A new commentary in The Lancet examines the challenges of proving disease-modifying therapies for Parkinson's, focusing on the prasinezumab trials. The PASADENA and PADOVA studies tested an antibody targeting aggregating forms of α-synuclein, a protein linked to the disease. Researchers note that while the concept is appealing, demonstrating efficacy remains elusive.
The commentary underscores a lack of consensus on optimal trial design for such therapies. Prasinezumab, designed to hit the C-terminal of aggregated α-synuclein, was administered via monthly intravenous infusions. The PASADENA trial evaluated two doses in treatment-naive patients or those already on MAO-B inhibitors.
Despite the biological rationale, the trials have not yielded clear proof of slowing disease progression. The commentary suggests that the field still grapples with how best to measure meaningful change in Parkinson's patients. No specific efficacy data or numerical outcomes are detailed in the source.
These findings have significant implications for future research and drug development in neurodegeneration. If prasinezumab cannot demonstrate robust effects, it may shift focus toward alternative targets or trial methodologies. Patients and investors alike await clearer answers.
The commentary authors call for refined endpoints and longer study durations to capture potential benefits. They emphasize that negative results still provide critical insights for the next generation of therapies.